By Luc Cohen
NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
The Foster City, California-based company disclosed the potential resolution with the Manhattan U.S. Attorney's office in a Friday afternoon securities filing.
Gilead said it had received a subpoena in 2017, but did not provide additional details about the probe in its filing.
The company, which first disclosed the probe in 2018, said in a statement on Monday: "We have taken a litigation accrual for a potential settlement."
A spokesman for the Manhattan U.S. Attorney's office declined to comment.
Promotional speaker programs in which doctors are paid by drugmakers to deliver lectures about their products have drawn past Justice Department scrutiny.
In 2020, Swiss drugmaker Novartis NOVN.S paid more than $600 million to settle with the Manhattan U.S. Attorney over claims its speaker program was a cover for paying bribes to doctors to prescribe its medication.
Novartis at the time said it was "committed to doing what is right" and had established an enhanced compliance framework.
Gilead's HIV drug sales rose 16% to $5.45 billion in the fourth quarter of 2024, contributing to a surge in its share price.
The company expects to launch a new drug, lenacapavir, for protecting against HIV infection later this year.
(Reporting by Luc Cohen in New York; Editing by Bill Berkrot)
((luc.cohen@thomsonreuters.com; +1 646 361 1622; Reuters Messaging: Twitter: @cohenluc))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。